TY - JOUR
T1 - Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation
AU - Sondergaard, B C
AU - Henriksen, K
AU - Wulf, H
AU - Oestergaard, S
AU - Schurigt, U
AU - Bräuer, R
AU - Danielsen, I
AU - Christiansen, C
AU - Qvist, P
AU - Karsdal, M A
PY - 2006/8
Y1 - 2006/8
N2 - OBJECTIVE: Both matrix metalloprotease (MMP) activity and cathepsin K (CK) activity have been implicated in cartilage turnover. We investigated the relative contribution of MMP activity and CK activity in cartilage degradation using ex vivo and in vivo models.METHODS: Bovine articular cartilage explants were stimulated with oncostatin M (OSM) 10 ng/ml and tumor necrosis factor-alpha (TNF-alpha) 20 ng/ml in the presence or absence of the broad-spectrum MMP inhibitor GM6001 and the cysteine protease inhibitor, E64. Cartilage degradation was evaluated in the conditioned medium by glycosaminoglycans (GAG), hydroxyproline, and cross-linked C-telopeptide fragments of type II collagen (CTX-II), which were compared to immunohistochemical evaluations of proteoglycans and CTX-II. We assessed MMP expression by gelatine zymography and CK expression by immunohistochemistry. In vivo, CTX-II release was measured from CK-deficient mice.RESULTS: OSM and TNF-alpha combined induced significant (P<0.01) increase in cartilage degradation products measured by hydroxyproline and CTX-II compared to vehicle control. The cytokines potently induced MMP expression, assessed by zymography, and CK expression investigated by immunohistochemistry. Inhibition of MMP activity completely abrogated hydroxyproline and CTX-II release (P<0.01) and GAG release (P<0.05). In contrast, E64 resulted in increased CTX-II release by 100% (P<0.05) and inhibited GAG release by 30%. Up-regulation of CTX-II fragments was confirmed in vivo in CK null mice.CONCLUSION: Inhibition of MMP activity reduced both proteoglycan loss and type II collagen degradation. In contrast, inhibition of cysteine proteases resulted in an increase rather than a decrease in MMP derived fragments of collagen type II degradation, CTX-II, suggesting altered collagen metabolism.
AB - OBJECTIVE: Both matrix metalloprotease (MMP) activity and cathepsin K (CK) activity have been implicated in cartilage turnover. We investigated the relative contribution of MMP activity and CK activity in cartilage degradation using ex vivo and in vivo models.METHODS: Bovine articular cartilage explants were stimulated with oncostatin M (OSM) 10 ng/ml and tumor necrosis factor-alpha (TNF-alpha) 20 ng/ml in the presence or absence of the broad-spectrum MMP inhibitor GM6001 and the cysteine protease inhibitor, E64. Cartilage degradation was evaluated in the conditioned medium by glycosaminoglycans (GAG), hydroxyproline, and cross-linked C-telopeptide fragments of type II collagen (CTX-II), which were compared to immunohistochemical evaluations of proteoglycans and CTX-II. We assessed MMP expression by gelatine zymography and CK expression by immunohistochemistry. In vivo, CTX-II release was measured from CK-deficient mice.RESULTS: OSM and TNF-alpha combined induced significant (P<0.01) increase in cartilage degradation products measured by hydroxyproline and CTX-II compared to vehicle control. The cytokines potently induced MMP expression, assessed by zymography, and CK expression investigated by immunohistochemistry. Inhibition of MMP activity completely abrogated hydroxyproline and CTX-II release (P<0.01) and GAG release (P<0.05). In contrast, E64 resulted in increased CTX-II release by 100% (P<0.05) and inhibited GAG release by 30%. Up-regulation of CTX-II fragments was confirmed in vivo in CK null mice.CONCLUSION: Inhibition of MMP activity reduced both proteoglycan loss and type II collagen degradation. In contrast, inhibition of cysteine proteases resulted in an increase rather than a decrease in MMP derived fragments of collagen type II degradation, CTX-II, suggesting altered collagen metabolism.
KW - Animals
KW - Arthritis, Experimental
KW - Biomarkers/analysis
KW - Cartilage, Articular/drug effects
KW - Cathepsin K
KW - Cathepsins/deficiency
KW - Cattle
KW - Collagen Type I/analysis
KW - Cysteine Endopeptidases/metabolism
KW - Cysteine Proteinase Inhibitors/pharmacology
KW - Cytokines/pharmacology
KW - Dipeptides/pharmacology
KW - Extracellular Matrix/enzymology
KW - Glycosaminoglycans/analysis
KW - Hydroxyproline/analysis
KW - Immunohistochemistry/methods
KW - Leucine/analogs & derivatives
KW - Matrix Metalloproteinase Inhibitors
KW - Matrix Metalloproteinases/metabolism
KW - Mice
KW - Mice, Knockout
KW - Oncostatin M/pharmacology
KW - Osteoarthritis, Knee/enzymology
KW - Peptides/analysis
KW - Stimulation, Chemical
KW - Tissue Culture Techniques
KW - Tumor Necrosis Factor-alpha/pharmacology
U2 - 10.1016/j.joca.2006.01.016
DO - 10.1016/j.joca.2006.01.016
M3 - Article
C2 - 16563811
SN - 1063-4584
VL - 14
SP - 738
EP - 748
JO - Osteoarthritis and Cartilage
JF - Osteoarthritis and Cartilage
IS - 8
ER -